BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 34125421)

  • 21. Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.
    Schuster SJ; Zhang J; Yang H; Agarwal A; Tang W; Martinez-Prieto M; Bollu V; Kuzan D; Maziarz RT; Kersten MJ
    Leuk Lymphoma; 2022 Apr; 63(4):845-854. PubMed ID: 34978255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.
    Van Le H; Van Naarden Braun K; Nowakowski GS; Sermer D; Radford J; Townsend W; Ghesquieres H; Menne T; Porpaczy E; Fox CP; Schusterbauer C; Liu FF; Yue L; De Benedetti M; Hasskarl J
    Leuk Lymphoma; 2023 Mar; 64(3):573-585. PubMed ID: 36755418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
    Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
    J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
    Siddiqi T; Maloney DG; Kenderian SS; Brander DM; Dorritie K; Soumerai J; Riedell PA; Shah NN; Nath R; Fakhri B; Stephens DM; Ma S; Feldman T; Solomon SR; Schuster SJ; Perna SK; Tuazon SA; Ou SS; Papp E; Peiser L; Chen Y; Wierda WG
    Lancet; 2023 Aug; 402(10402):641-654. PubMed ID: 37295445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.
    Parker C; Liu FF; Deger KA; Franco-Villalobos C; Proskorovsky I; Keating SJ; Sorensen S
    Adv Ther; 2023 May; 40(5):2355-2374. PubMed ID: 36947328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma.
    Elmacken M; Peredo-Pinto H; Wang C; Xu Z; Tegenge M; Jaigirdar AA; Theoret MR; Purohit-Sheth T; Kasamon YL
    Clin Cancer Res; 2024 Jun; 30(11):2309-2316. PubMed ID: 38324398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma.
    Oluwole OO; Chen JMH; Chan K; Patel AR; Jansen JP; Keeping S; Zheng Y; Snider JT; Locke FL
    Leuk Lymphoma; 2022 Dec; 63(13):3052-3062. PubMed ID: 36048026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.
    Badaracco J; Gitlin M; Keating SJ
    Transplant Cell Ther; 2023 Jan; 29(1):59.e1-59.e6. PubMed ID: 36272529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma.
    Duarte C; Kamdar M
    Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e390802. PubMed ID: 37098236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel.
    Olson NE; Ragan SP; Reiss DJ; Thorpe J; Kim Y; Abramson JS; McCoy C; Newhall KJ; Fox BA
    Mol Cancer Ther; 2023 Mar; 22(3):406-418. PubMed ID: 36595660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
    Abramson JS; Johnston PB; Kamdar M; Ibrahimi S; Izutsu K; Arnason J; Glass B; Mutsaers P; Lunning M; Braverman J; Liu FF; Crotta A; Montheard S; Previtali A; Guo S; Shi L; Solomon SR
    Blood Adv; 2022 Dec; 6(23):5969-5979. PubMed ID: 36149968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
    Sehgal A; Hoda D; Riedell PA; Ghosh N; Hamadani M; Hildebrandt GC; Godwin JE; Reagan PM; Wagner-Johnston N; Essell J; Nath R; Solomon SR; Champion R; Licitra E; Fanning S; Gupta N; Dubowy R; D'Andrea A; Wang L; Ogasawara K; Thorpe J; Gordon LI
    Lancet Oncol; 2022 Aug; 23(8):1066-1077. PubMed ID: 35839786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
    Ghilardi G; Paruzzo L; Patel V; Svoboda J; Chong ER; Fardella E; Chong EA; Gabrielli G; Nasta SD; Landsburg DJ; Carter J; Pajarillo R; Barta SK; White G; Weber E; Napier E; Porter DL; Garfall AL; Schuster SJ; Ruella M
    J Hematol Oncol; 2024 Apr; 17(1):19. PubMed ID: 38644469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma.
    Choe JH; Yu T; Abramson JS; Abou-El-Enein M
    Blood Adv; 2024 Jan; 8(2):484-496. PubMed ID: 38153350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
    Siddiqi T; Soumerai JD; Dorritie KA; Stephens DM; Riedell PA; Arnason J; Kipps TJ; Gillenwater HH; Gong L; Yang L; Ogasawara K; Thorpe J; Wierda WG
    Blood; 2022 Mar; 139(12):1794-1806. PubMed ID: 34699592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma].
    Hanajiri R; Furukawa K; Nakashima M; Ushijima Y; Shimada K; Ishikawa Y; Terakura S; Murata M; Kiyoi H
    Rinsho Ketsueki; 2023; 64(3):167-174. PubMed ID: 37019669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan.
    Tsutsué S; Makita S; Asou H; Matsuda H; Yamaura R; Taylor TD
    Future Oncol; 2024 Apr; ():1-17. PubMed ID: 38597742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimating the Cost per Clinical Outcome of Second-Line Liso-Cel Versus Autologous Stem Cell Transplantation in Patients with Transplantation-Intended Relapsed/Refractory Large B Cell Lymphoma.
    Saeedian M; Badaracco J; Botros A; Gitlin M; Keating SJ
    Transplant Cell Ther; 2023 Nov; 29(11):712.e1-712.e7. PubMed ID: 37544410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis.
    Wu W; Zhou Y; Wang Y; Keramat SA; Balasooriya NN; Zhao Z; Yang Y; Comans T; Dong H
    Appl Health Econ Health Policy; 2023 Sep; 21(5):773-783. PubMed ID: 37356080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Next-Generation Chimeric Antigen Receptor T-cells.
    Yi D; Gergis M; Hsu J; Yang Y; Bi X; Aljurf M; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):117-121. PubMed ID: 36537905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.